Loading clinical trials...
Loading clinical trials...
A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to obtain patient preferences in direct correlation with clinical data from patients suffering from NSCLC (stage IIIB / IV) who are in transition from 1st to 2nd line treatment, and to gain utility scores by health state derived from patients' perceived value and taken from their perspective.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Berlin, Germany
Research Site
Essen, Germany
Research Site
Heidelberg, Germany
Research Site
Hemer, Germany
Research Site
Karlsruhe, Germany
Research Site
Löwenstein, Germany
Research Site
München, Germany
Research Site
Trier, Germany
Start Date
April 1, 2009
Completion Date
October 1, 2009
Last Updated
December 10, 2010
120
ESTIMATED participants
Lead Sponsor
AstraZeneca
NCT06498635
NCT06305754
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions